Breast Cancer Update, Issue 3, 2019 — Part 2: Our interview with
Dr Kaklamani highlights the following topics as well as cases from
her practice:
Efficacy and safety of the novel SERD elacestrant for
ER-positive breast cancer; Phase III EMERALD trial evaluating
elacestrant versus endocrine therapy (00:00)
Incidence of ESR1 mutations; activity of elacestrant after
disease progression on fulvestrant and a CDK4/6 inhibitor
(02:14)
Results from the Phase II ANETT trial of the mTORC1/2 inhibitor
TAK-228 with tamoxifen as neoadjuvant therapy for ER-positive
breast cancer (03:53)
Novel approaches under investigation in the neoadjuvant setting
(07:20)
Perspective on the use of neoadjuvant therapy to optimize
surgical outcomes for patients with ER-positive, HER2-negative
breast cancer (09:43)
Activity of CDK4/6 inhibitors for locally advanced ER-positive
breast cancer (11:30)
Case: A woman in her late 60s with
ER-positive, HER2-negative breast cancer and 1 of 3 positive
axillary lymph nodes receives a 21-gene assay RS of 18 (13:49)
Role of the 21-gene expression assay in predicting chemotherapy
benefit for patients with ER-positive breast cancer (15:56)
Clinical and genomic risk to guide the use of adjuvant therapy
for breast cancer (19:11)
Case: A premenopausal woman in her late 40s
with ER-positive, HER2-negative, node-negative breast cancer
receives a RS of 19 (23:19)
Clinical implications of the TAILORx trial comparing
chemoendocrine therapy to endocrine therapy for patients with
ER-positive, node-negative breast cancer and an intermediate RS
(25:00)
Tailoring adjuvant endocrine therapy for premenopausal women
with ER-positive breast cancer (27:54)
Benefit of endocrine therapy with or without chemotherapy for
patients with ER-positive breast cancer and an intermediate RS;
consideration of clinical and genomic risk in assessing the
likelihood of disease recurrence (30:54)
Case: A woman in her early 40s with
ER-positive, HER2-negative breast cancer and metastases in the
liver and bones attains a partial response to ribociclib in
combination with endocrine therapy (35:24)
Benefit with CDK4/6 inhibitors versus chemotherapy for
ER-positive breast cancer with visceral metastases (37:57)
Efficacy of ribociclib in premenopausal women; QT prolongation
associated with ribociclib/tamoxifen (40:54)
Comparison of the efficacy and toxicity profiles of
abemaciclib, palbociclib and ribociclib for women with ER-positive
mBC (42:24)
Activity of CDK4/6 inhibitors as monotherapy; CNS penetration
of CDK4/6 inhibitors (45:47)
Monitoring and management of side effects associated with
CDK4/6 inhibitors (48:07)
Case: A woman in her mid-50s initially
diagnosed with Stage II ER-positive breast cancer develops
metastatic disease to the bone 8 years later and receives
palbociclib and anastrozole (50:54)
Perspective on the use of multiplex genomic assays to guide
treatment decision-making for patients with ER-positive mBC
(53:35)
Results of the Phase III SOLAR-1 trial evaluating alpelisib for
patients with ER-positive advanced breast cancer (55:54)
Tolerability of alpelisib for patients with ER-positive breast
cancer (57:54)
Sequencing everolimus and alpelisib after disease progression
on a CDK4/6 inhibitor (1:00:06)
Case: A postmenopausal woman in her mid-30s
with ER-positive mBC and BRCA2 and PIK3CA mutations receives
talazoparib in the third-line setting (1:01:46)
Choice of PARP inhibitor for patients with advanced breast
cancer and BRCA mutations (1:04:58)
Response and side-effect profiles of alpelisib (1:06:10)
Selection and sequencing of therapy for patients with mBC and
germline BRCA mutations (1:07:00)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.